Press Releases

Dec 29, 2021 11:15am EST

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

Dec 16, 2021 2:45pm EST

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

Dec 14, 2021 11:50am EST

Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion

Dec 08, 2021 7:30am EST

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Nov 10, 2021 9:00am EST

Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes

Nov 03, 2021 7:30am EDT

Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4

Nov 01, 2021 9:00am EDT

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol

Oct 13, 2021 11:00am EDT

Lexaria's Technology Proven to Deliver Oral THC More Effectively

Oct 05, 2021 9:05am EDT

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

Sep 16, 2021 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment